(Q50588155)

16 March 2018

title

Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. (English)

1 reference

16 March 2018

0 references

1 reference

1 reference

1 reference

1 reference

Zoulim F

1

1 reference

16 March 2018

Haem J

2

1 reference

16 March 2018

Ahmed SS

3

1 reference

16 March 2018

Chossegros P

4

1 reference

16 March 2018

Habersetzer F

5

1 reference

16 March 2018

Chevallier M

6

1 reference

16 March 2018

Bailly F

7

1 reference

16 March 2018

Trépo C

8

1 reference

16 March 2018

publication date

1 May 1998

1 reference

16 March 2018

Journal of Viral Hepatitis

published in

1 reference

16 March 2018

volume

5

1 reference

16 March 2018

issue

3

1 reference

16 March 2018

page(s)

193-198

1 reference

16 March 2018

The treatment of chronic viral hepatitis

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00099.X

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00099.X

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00099.X

Clinical outcomes after transfusion-associated hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00099.X

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00099.X

Nucleoside analogs in the treatment of chronic viral hepatitis. Efficiency and complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00099.X

Ribavirin treatment for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00099.X

A pilot study of ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00099.X

Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00099.X

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00099.X

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00099.X

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00099.X

Oral ribavirin for prevention of severe liver disease caused by hepatitis C virus during allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00099.X

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00099.X

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00099.X

Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00099.X

Comparison of HCV RNA assays for the detection and quantification of hepatitis C virus RNA levels in serum of patients with chronic hepatitis C treated with interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00099.X

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00099.X

Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00099.X

Prolonged therapy of chronic hepatitis C with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00099.X

10.1046/J.1365-2893.1998.00099.X

21 January 2018

Identifiers

DOI

1 reference

16 March 2018

1 reference

16 March 2018